A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight

The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.

开始日期2026-09-30

申办/合作机构

Zealand Pharma A/S

NCT07682818

/ Recruiting临床1期

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Hepatic Function

This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities.
The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.

开始日期2026-05-18

申办/合作机构

Zealand Pharma A/S

NCT07338214

/ Completed临床1期

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations in Participants With a BMI ≥27.0 kg/m²

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases.
The goal is to learn how the same single dose of petrelintide, given using different concentrations, works in the body when given to participants with a BMI at, or above, 27kg/m2.
The main questions it aims to answer are:
1. Are there differences in how the body absorbs, distributes, metabolises and excretes petrelintide when same single dose petrelintide is given using different concentrations?
2. Are there differences in safety of petrelintide when same single dose petrelintide is given using different concentrations?
Participants will:
Visit the study center 10 times for tests and blood sampling (9 day ambulatory visits and 1 in-house visit of 4 consecutive days with sleeping 3 nights at the study center).
Petrelintide will be given once as a single injection in a skin fold of the abdomen on Day 1. The participants will be monitored until approximately Day 50.

开始日期2025-12-17

申办/合作机构

Zealand Pharma A/S

[+1]

100 项与 Petrelintide 相关的临床结果

登录后查看更多信息

100 项与 Petrelintide 相关的转化医学

登录后查看更多信息

100 项与 Petrelintide 相关的专利（医药）

登录后查看更多信息

项与 Petrelintide 相关的文献（医药）

2026-07-01·DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Article

作者: Macura, Stanislava ; Brændholt Olsen, Minna ; Heise, Tim ; Griffin, Jon ; Fredsted Hagen, Berith ; Hesse, Dan ; Hövelmann, Ulrike

ABSTRACT:

Aims:

Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials.

Materials and Methods:

Both trials were randomized, placebo‐controlled, and double‐blind. The SAD trial assessed subcutaneous (SC) petrelintide doses of 0.04–2.4 mg and a 0.35 mg intravenous dose. The MAD trial evaluated 6 once‐weekly SC doses of 0.6 and 1.2 mg (part 1), and 16 once‐weekly doses escalated every 2 weeks to target doses of 2.4, 4.8, and 9.0 mg (part 2). The SAD and MAD part 1 trials enrolled normal or overweight adults; MAD part 2 enrolled adults with overweight or obesity.

Results:

Petrelintide was well tolerated, with no serious or severe treatment‐emergent adverse events (TEAEs). In both trials, the most common TEAEs included gastrointestinal (GI) disorders, most of which were mild. One participant discontinued treatment due to GI TEAEs. Nausea, the most common GI TEAE, occurred in 16.7%–33.3% of participants receiving petrelintide versus 16.7% for placebo in MAD part 2, while diarrhoea was rare and vomiting was only experienced by the participant who discontinued. Petrelintide was slowly absorbed, had a half‐life of ~10 days, showed steady‐state dose proportionality, and reduced body weight by up to 8.6% after 16 weeks.

Conclusion:

Petrelintide appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss. These findings support further development of petrelintide as an effective weight‐management medication, with potential for improved GI tolerability over existing therapies.

2026-03-01·VASCULAR PHARMACOLOGY

Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies

Review

作者: Rejili, Mokhtar ; Sahoo, Samir ; Haouala, Faouzi ; Khan, Yumna ; Pal, Amrita ; Arora, Vimal ; Ganesan, Subbulakshmi ; Hussain, Md Sadique

Obesity is a chronic, relapsing metabolic disorder driven by complex genetic and environmental factors, leading to an imbalance in energy regulation. Despite the presence of GLP-1 receptor agonists with induced mild weight loss, there are significant unmet clinical needs with poor efficacy and tolerability problems. Amylin, a neuroendocrine hormone co-released with insulin, controls hunger, gastric motility, glucagon secretion, and energy metabolism via divergent amylin receptor (AMYR) subtypes (1-3), namely the calcitonin receptor (CTR) and the receptor activity-modifying proteins (RAMPs). Novel insight into the molecular make-up of AMYRs and central signaling reinforces its key function in modulating homeostatic and hedonic feeding mechanisms. The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists (AMYRAs), including pramlintide and cagrilintide, KBP-series DACRAs, and investigational drugs, including ZP8396 and amycretin. The agents show enhanced pharmacokinetics, synergy with GLP-1 receptor agonist, and favorable impact on weight regulation and metabolic plasticity. Genetic CALCR and RAMP mutations, new delivery approaches, and dual therapy by digital health technologies and bariatric surgery are also discussed in this review. Of particular interest, amylin-derived medications can have advantages over weight loss but definite disease-modifying action remains to be determined. Taken together, AMYRAs represent a potential category of therapeutics with promising disease-modifying effects that goes beyond weight loss, providing fresh perspectives for precision obesity management by 2030.

2026-03-01·PEPTIDES

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

Review

作者: Flatt, Peter R ; Bailey, Clifford J ; Conlon, J Michael

The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weight loss, suppress prandial glucagon release and reduce prandial hyperglycaemia. Recent understanding of the heterodimeric structure of amylin-calcitonin receptor complexes and of amylin structure-function properties has assisted the design of a second generation of non-aggregating, long-acting amylin analogues. These are now advancing in clinical development and promise to provide an effective additional resource for the management of obesity and type 2 diabetes. Amongst these agents is the dual AMYR/ calcitonin-receptor (CTR) agonist, cagrilintide that has also been co-formulated into a once weekly subcutaneous injection with the long-acting glucagon-like peptide-1receptor (GLP-1R) agonist, semaglutide (CagriSema). In clinical trials, CagriSema has achieved greater effects than either component alone. A unimolecular AMYR/CTR/GLP-1R multi-agonist peptide, amycretin has been developed for weekly injection and as a once-daily tablet. Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234. Other analogues with marked efficacy in preclinical studies, including non-peptide AMYR agonists are under development. Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver disease, diabetes-associated kidney complications and resistant hypertension.

244

项与 Petrelintide 相关的新闻（医药）

2026-07-24

·生物制品圈

罗氏管线大清理

7月23日，罗氏交出了一份不错的半年报。集团营收303.64亿瑞士法郎，同比增长6%。制药业务236.29亿法郎，同样增长6%。但在财报会上，真正引发行业关注的不是这些数字，而是一连串被“砍掉”的管线。其中最引人注目的，是RG6382，一款靶向CD19和CD3的双特异性T细胞衔接器（TCE），正在系统性红斑狼疮（SLE）的1期临床中接受评估。罗氏发言人解释：“审查现有数据后，已明确该分子不具备在该适应症中继续推进所需的特性。”鉴于SLE是该资产的主要适应症，此次决定标志着其开发的完全终止。 “概率很低”的四个字，值多少钱？ RG6382不是孤例。这次管线清理波及多个阶段。在2期，罗氏砍掉了CT-868。一款从Carmot Therapeutics收购来的每日一次GLP-1/GIP双受体激动剂。有意思的是，CT-868在1型糖尿病中刚刚拿出了积极的2期数据。但罗氏的决定是：资源集中到同属Carmot资产的每周一次GLP-1/GIP激动剂enicepatide上。公司认为集中推进该计划“更有意义”，并称enicepatide在血糖控制方面具备同病最佳潜力。另一款被终止的2期项目是抗Tie2激动剂RG6351，曾用于糖尿病黄斑水肿（DME）。罗氏对数据的审视显示其击败Vabysmo的“概率很低”。这项研究反而强化了Vabysmo通过双重抑制VEGF/Ang-2为DME患者提供强效Tie2通路激活的判断。 “概率很低”这四个字，浓缩了新药研发最残酷的真相。一个分子的命运，往往就取决于数据读出时那一点微弱的差异。在更早期的1期管线中，BRAF抑制剂mosperafenib在实体瘤的试验虽显示出阳性数据，但试验已于4月关闭，罗氏认为将其授权给合适合作伙伴是最好的路径。另一款实体瘤候选药物RG6468也因1期数据审查后被停掉。此外，本月早些时候已宣布放弃的亨廷顿病项目也得到再次确认，包括与Ionis Pharmaceuticals合作、处于2期的tominersen。砍掉一个TCE，守住一个战略但这个故事的另一面更有意思。罗氏砍掉了RG6382这款TCE，却并没有退出自身免疫细胞疗法领域。 2024年，罗氏以15亿美元收购Poseida Therapeutics。Poseida的管线中包含一款BCMAxCD19 CAR-T。罗氏制药首席执行官Teresa Graham在财报会上明确表示：“我们确实打算继续开发（自身免疫性疾病的细胞疗法），并希望很快能提供更多更新。” 这一砍一留之间，透露出罗氏在自免领域的战略取舍：放弃TCE这个技术路径，押注CAR-T这个更具变革潜力的方向。这不是一个容易的决定。 CD3/CD19双抗赛道正在加速，默沙东2024年8月以13亿美元收购了同靶点双抗CN201；德琪医药的ATG-201已在中国获批IND；Xencor的XmAb657已于2025年底进入临床。罗氏在这个拥挤的赛道中选择退出，意味着承认自己的分子不够好，意味着承认竞争对手可能走得更快。在新药研发的世界里，承认失败有时比坚持更需要勇气。 “晚期末线太满了” 罗氏CEO Thomas Schinecker在财报电话会上有一句话值得玩味：“我们的晚期末线太满了，如果再添加晚期项目，我们得考虑如何重新分配更多资金。” 目前罗氏正在推进的管线中，有多达19款药物有望在2030年前上市。 Schinecker甚至说：“即使不是所有都能成功，我们未来十年的增长也已经做好了准备。” 19个潜在上市产品，对于一个年研发投入超过125亿美元的药企来说，这个数字意味着什么？意味着罗氏正在从一个“肿瘤专科药企”，加速向全疾病领域平台转型。肥胖症领域的petrelintide（与Zealand Pharma合作）和enicepatide（来自Carmot收购）、阿尔茨海默病领域的trontinemab、乳腺癌领域的giredestrant。罗氏预测这些资产中每一款的峰值销售都超过30亿美元。在这种背景下，砍掉几个1期、2期的分子，与其说是“失败”，不如说是战略聚焦的必然代价。当一个公司的晚期末线“太满了”，早期项目就必须接受更严苛的审视。不纠结的定力正如罗氏中国首位本土总裁曾说自己的管理风格是“求其上”与“不纠结”：设定高目标，但一旦做出判断就不再纠结。罗氏全球正在做的事情，本质上也是“不纠结”。在GLP-1赛道，放弃每日一次的CT-868，押注每周一次的enicepatide，不纠结。在自免领域，放弃TCE这个技术路径，押注CAR-T，不纠结。在亨廷顿病这个屡战屡败的领域，干脆彻底退出，同样不纠结。创新药企最怕的不是失败，而是不敢承认失败。罗氏这次财报季的管线清理，恰恰展示了一家百年药企的定力：敢于在数据面前说“不”，敢于承认“这个分子不够好”，敢于把资源从“还行”的项目挪到“可能改变游戏规则”的项目上。半年报的数字是好看的，但真正定义罗氏未来的，是这些被砍掉的项目背后那个更清醒、更聚焦的战略选择。砍掉一个TCE，为的是守住一个更大的未来。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

免疫疗法并购财报临床1期细胞疗法

2026-07-23

·MIR医学仪器与试剂

罗氏半年报：实现3%增长并大幅抵消中国集采影响，诊疗闭环优势突出！

2026年7月23日，罗氏发布2026半年业绩报告。说明：CER = 固定汇率（constant exchange rates）；CHF 瑞士法郎；IFRS 国际财务报告准则 Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc 罗氏在 2026 年上半年延续强劲发展态势：按固定汇率计算销售额增长 6%；受瑞士法郎大幅升值影响，以瑞士法郎计价销售额下降 2%。 Highlights 年报亮点 US Priority Reviews for giredestrant in an early-stage breast cancer, Enspryng in thyroid eye disease, Tecentriq in colon cancer as well as Gazyva/Gazyvaro in idiopathic nephrotic syndrome and primary membranous nephropathy, two autoimmune diseases affecting the kidneys 美国FDA授予多项优先审评资格，包括：giredestrant用于早期乳腺癌，Enspryng用于甲状腺眼病，泰圣奇（Tecentriq）用于结肠癌，佳罗华（Gazyva/Gazyvaro）用于两种肾脏自身免疫病：特发性肾病综合征、原发性膜性肾病 US acceptance of a supplemental Biologics License Application for the Lunsumio and Polivy combination for blood cancer and Gazyva/Gazyvaro for systemic lupus erythematosu 美国受理两项生物制品补充许可申请：Lunsumio联合Polivy治疗血液肿瘤；佳罗华用于系统性红斑狼疮 Positive phase III data on divarasib in lung cancer; presentation of promising data on fenebrutinib in multiple sclerosis (phase III), Gazyva/Gazyvaro in three autoimmune diseases (phase III) and enicepatide (CT-388) and petrelintide in obesity (phase II) 临床关键数据公布：divarasib治疗肺癌III期研究取得阳性结果公布多项极具前景临床数据：fenebrutinib治疗多发性硬化（III期）；佳罗华用于三类自身免疫病（III期）；enicepatide（CT-388）、petrelintide治疗肥胖（II期） Launch of Axelios 1, a transformative next-generation sequencing platform based on the innovative SBX technology, enabling the fastest DNA sequencing at scale 推出新一代测序平台**Axelios 1**：依托创新SBX技术，实现规模化超高速DNA测序，具备变革意义 EU CE mark for two blood tests: Elecsys pTau217 to detect Alzheimer’s pathology and Elecsys IGRA TB to identify latent tuberculosis infection 两款血液检测获欧盟CE认证：Elecsys pTau217：检测阿尔茨海默病理标志物；Elecsys IGRA TB：筛查潜伏性结核感染。 US approval for Ventana PTEN (SP218) RxDx Assay, the first companion diagnostic to assess the levels of a key protein in prostate cancer Ventana PTEN (SP218)伴随诊断试剂获美国批准，**首款评估前列腺癌关键蛋白表达水平的伴随诊断产品** Global collaboration agreement with Nurix Therapeutics for the BTK degrader bexobrutideg across malignant haematology, immunology and neurology 与Nurix Therapeutics达成全球合作协议，共同开发BTK降解剂bexobrutideg，覆盖血液恶性肿瘤、免疫学、神经疾病领域 Agreement to acquire PathAI to transform AI-driven diagnostics 签署收购PathAI协议，布局人工智能驱动诊断业务 Outlook for 2026 confirmed. 敲定2026业绩指引 Outlook for 2026 2026年全年业绩指引 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs. 罗氏（瑞交所：RO、ROP；场外市场：RHHBY）预期： - 集团全年销售额（固定汇率口径）实现**中个位数增幅** - 核心每股收益目标实现**高个位数增长（固定汇率口径）** - 计划继续提高以瑞士法郎计价的股息 Group results 集团整体经营情况 In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. 2026年上半年，罗氏集团销售额固定汇率下上涨6%，瑞郎计价降至304亿瑞郎，同比下滑2%，核心驱动力为药物与诊断方案需求旺盛。瑞士法郎对多数货币（尤其美元）升值，造成瑞郎口径财报与固定汇率口径存在显著差异。 Core operating profit was +10% at CER (-1% in CHF) to CHF 11.9 billion, driven by higher sales and other revenue. Core earnings per share were +9% at CER (-2% in CHF). 核心营业利润固定汇率下增长10%（瑞郎口径-1%），达119亿瑞郎；核心每股收益固定汇率上涨9%（瑞郎口径-2%）。 IFRS operating profit was -6% in CHF to CHF 9.7 billion. IFRS diluted earnings per share were -8% in CHF. The IFRS results were impacted by the appreciation of the Swiss franc. IFRS口径营业利润97亿瑞郎，同比下滑6%；IFRS摊薄每股收益瑞郎口径下降8%，汇率走强是主要拖累因素。 Diagnostics Division 诊断事业部业务 The Diagnostics Division’s sales were +3% at CER, -3% when reported in CHF, to CHF 6.7 billion, driven by growth in demand for immunodiagnostic and clinical chemistry products as well as pathology and molecular solutions. This growth more than offset the impact of healthcare pricing reforms in China. 诊断事业部销售额67亿瑞郎，固定汇率+3%，瑞郎计价-3%；受益于免疫、生化、病理、分子诊断需求提升，该增长部分大幅抵消了中国医疗价格改革带来的影响。区域拆分 Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, -1% when reported in CHF, driven by higher sales of immunodiagnostic products, the clinical chemistry portfolio and molecular solutions. 欧非中东（EMEA）：固定汇率+3%，瑞郎-1%，生化、免疫、分子诊断全线增长 In North America, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas. 北美：固定汇率+8%，瑞郎-1%，中心实验室、病理实验室业务双增长 Sales in Asia-Pacific were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region. 亚太：固定汇率-5%，瑞郎-12%；中国集采调价拖累，区域其他市场生化、免疫诊断实现增长 In Latin America, sales were +10% at CER, or +5% when reported in CHF. 拉美：固定汇率+10%，瑞郎+5% Diagnostics sales 诊断业务客户板块拆分其他相关动态 1. **阿尔茨海默病一体化管线** 在AAIC大会公布trontinemab长期临床数据，并启动临床前阿尔茨海默III期PrevenTRON研究；同步展示Elecsys pTau217血液检测在一二级医院的应用数据。 2. **与Nurix合作bexobrutideg** 全球共同开发BTK蛋白降解剂，覆盖B细胞恶性肿瘤、慢性自发性荨麻疹、多发性硬化；机制可克服现有BTK抑制剂耐药问题。 3. **肥胖管线数据发布（ADA 2026）** enicepatide（CT-388）、petrelintide两项II期研究展示优异减重效果；即将启动复方制剂II期多臂试验。 4. **肿瘤数据ASCO 2026** giredestrant两项关键III期lidERA、persevERA数据公布，重塑早期乳腺癌内分泌治疗格局；同步展示9款肿瘤创新药（双抗、ADC、血脑屏障穿透分子）。 5. **眼科管线ARVO 2026** 法瑞西单抗真实世界数据确认强效消退黄斑积液；Susvimo长效给药方案持续降低治疗负担；共计45篇摘要、20场口头报告覆盖五大视网膜疾病。诊断板块重要产品进展 1. **cobas HDV丁肝检测试剂盒** 全球首款高通量全自动丁肝检测方案；全球约1200万丁肝感染者，病程进展更快、更易诱发肝衰竭与肝癌，配合新型丁肝药物实现诊断-治疗闭环。 2. **Elecsys IGRA TB潜伏结核血液检测（欧盟CE）** 搭载cobas免疫平台，全程自动化；检测耗时缩短至19分钟，助力WHO消除结核目标。 3. **Axelios 1下一代测序平台** 依托SBX技术，兼顾速度、通量、成本；研究场景可实现当日完成全基因组测序，未来有望拓展临床应用。 4. **Ventana PTEN (SP218)伴随诊断（FDA获批）** 首款前列腺癌PTEN蛋白检测伴随诊断，筛选适合Truqap联合治疗的患者；PTEN缺失预示前列腺癌进展更快。 5. **肝病综合检测面板** 搭载认证算法LiverPRO，仅需年龄+常规血检即可筛查肝纤维化；覆盖全球15亿慢性肝病人群，实现纤维化风险筛查至肝癌监测全程管理。 6. **Elecsys pTau217阿尔茨海默血液检测（CE）** 单试剂方案，通过抽血判断脑内淀粉样蛋白病理，替代部分脑脊液与PET检查；当前痴呆平均确诊周期长达3.5年，75%痴呆患者未得到诊断。 7. **收购PathAI协议** 补强AI数字病理；结合罗氏伴随诊断优势，加速新药研发、生物标志物发现，推动个体化诊疗普及。 Roche CEO Thomas Schinecker: 罗氏首席执行官Thomas Schinecker发言 “Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development. “上半年我们延续强劲发展势头，固定汇率下销售额增长6%，管线取得一系列重大临床进展。 We reported positive phase III data for divarasib, reinforcing its potential as a best-in-class therapy in advanced lung cancer. Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews: giredestrant in early-stage breast cancer, Enspryng in thyroid eye disease, Tecentriq in colon cancer and Gazyva/Gazyvaro in two autoimmune kidney diseases. divarasib III期研究取得阳性结果，进一步印证其有望成为晚期肺癌同类最优疗法。监管申报节奏显著提速，美国FDA授予五项优先审评资格：giredestrant用于早期乳腺癌、Enspryng用于甲状腺眼病、泰圣奇用于结肠癌，以及佳罗华治疗两类自身免疫性肾病。 In Diagnostics, we reached major milestones with the launch of our transformative, highly cost-effective Axelios 1 sequencing solution, alongside EU CE mark for key diagnostic tests, including the Elecsys pTau217 blood test for Alzheimer’s pathology and the Elecsys IGRA TBblood test, which delivers automated, scalable latent tuberculosis screening to laboratories worldwide. 诊断业务迎来多项里程碑：具备变革意义、高成本效益的新一代测序平台Axelios 1正式上市；多款核心检测产品拿到欧盟CE认证，包括用于阿尔茨海默病理检测的Elecsys pTau217血液检测、Elecsys IGRA结核检测，可为全球实验室提供自动化、规模化潜伏结核筛查方案。 Backed by our robust pipeline, we are well-positioned for sustained future growth. We confirm our outlook.” 依托强大产品管线，我们具备持续长期增长基础。我们坚定未来。” 资料链接（原文） - 演示文稿：http://www.roche.com/irp260723-a.pdf - 完整版演示文稿（附录）：http://www.roche.com/irp260723.pdf - 半年报全文：http://www.roche.com/hy26e.pdf - 制药管线手册：http://www.roche.com/pharmahy26.pdf - 诊断管线手册：http://www.roche.com/diahy26.pdf ※ 本文内容来自罗氏官网公开发布文章内容由“MIR医学仪器与试剂”编辑整理，转载请注明来源。精选荐读 2026年初数据透视：A股IVD企业市值更新刚刚更新！IFCC发布2026肌钙蛋白“封神榜”，此次看点有这些新王当立？！中国凝血市场当前谁主沉浮卫健委批复！互联网首诊来了，检验如何“在线”？检验健谈｜让“罕见”被看见：一场关于3.5亿患者的诊断技术攻坚从早筛到医共体，两会发出清晰信号，检验医学担大任！检验健谈 | 前移肾脏病防线，临床诊疗如何从“被动”到“主动”

2026-07-23

·丁香园 Insight 数据库

罗氏 2026H1：制药业务增长 6%，中国区收入 19 亿美元

7 月 23 日，罗氏发布财报，上半年营收 303.64 亿瑞士法郎（约合 386.72 亿美元，俺平均汇率计算：1 瑞士法郎= 1.2736 美元），同比增长 6%（按固定汇率计算，下同）。其中制药业务收入 236.29 亿瑞士法郎（约合 300.94 亿美元），同比增长 6%。来源：罗氏财报（下同）从地区来看，美国依然是罗氏的首要来源，上半年收入 122.29 亿瑞士法郎，同比增长 6%。中国区总营收 14.90 亿瑞士法郎 (约合 18.98 亿美元)，同比下滑 9%，主要受 2025 上半年流感药 Xofluza 高基数影响。上半年，罗氏业绩增长的主要驱动力来自于 Xolair（奥马珠单抗)、Hemlibra（艾美赛珠单抗）、 Ocrevus（奥瑞利珠单抗）、Phesgo（帕妥珠单抗曲妥珠单抗皮下制剂）和 Vabysmo（法瑞西单抗）。这些产品合计销售 110 亿瑞士法郎，同比增长 12%。其中 Ocrevus（奥瑞利珠单抗）依旧是最畅销产品，全球销售额为 34.7 亿瑞士法郎（约合 44.19 亿美元），同比增长 7%。此前，罗氏高调宣布，要成为肥胖前三玩家，同时计划在 2030 年后保持神经病学领域第一的地位。在 CVRM 领域，罗氏上半年公布了 enicepatide 和 petrelintide 的 II 期临床数据，下半年将启动 petrelintide、CT-996 用于肥胖的 III 期临床。在神经病学领域，罗氏上半年收入 49.7 亿瑞士法郎（约合 63.3 亿美元），同比上涨 9%，基本盘仍是 Ocrevus（奥瑞利珠单抗），贡献了总板块 70% 的收入。编辑：月牙封面来源：企业logo/站酷海洛免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。

100 项与 Petrelintide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	美国	Zealand Pharma A/S	2025-04-22
2型糖尿病	临床2期	美国	Roche Holding AG	2025-04-22
肥胖	临床2期	美国	Zealand Pharma A/S	2024-12-09
肥胖	临床2期	波兰	Zealand Pharma A/S	2024-12-09
肥胖	临床2期	罗马尼亚	Zealand Pharma A/S	2024-12-09
超重	临床1期	德国	Zealand Pharma A/S	2025-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ZUPREME 1 (ADA2026)	临床2期	肥胖	485	Petrelintide	餘積構鏇衊選膚醖簾壓(窪壓獵壓簾繭願積醖鏇) = 齋鬱淵獵壓選醖膚鑰範鏇鏇餘夢醖簾廠鏇壓鹽 (艱選鏇繭網蓋鬱願願築 ) 更多	积极	2026-06-20
				Placebo	醖憲窪夢繭願網願艱襯(襯選蓋觸膚衊遞觸餘夢) = 膚襯遞壓襯遞衊鹽鹽齋醖鹽淵築構夢餘築齋網 (鹹膚觸網鬱網餘積衊顧 )
NCT05096598 (ADA2026)	临床1期	体重下降	72	Petrelintide	鹹壓齋壓築繭選淵憲構(鹽繭憲願選鹽繭遞鏇選) = The incidence of gastrointestinal (GI) AEs was low with OW doses; vomiting occurred in one participant, who was also the only participant to discontinue due to GI AE 膚網願醖餘鹽範獵繭網 (壓衊淵夢壓獵醖製窪夢 )	积极	2026-06-20
				Placebo
NCT06662539 (ZUPREME-1, Company pipeline) 人工标引	临床2期	超重 \| 肥胖	493	petrelintide	築糧夢網網積繭獵壓餘(衊衊觸選鬱獵蓋鬱襯襯) = resulted in statistically significant and clinically meaningful weight loss. 糧製醖鬱鹽蓋鏇觸齋遞 (構構夢鏇顧獵膚選鏇糧 ) 达到更多	积极	2026-03-05
				Placebo
NCT05613387 (MAD, Biospace) 人工标引	临床1期	超重	48	Petrelintide	襯顧壓鹽鏇繭鹽蓋憲遞(衊願繭壓鏇齋觸鹽獵糧) = Petrelintide was assessed to be well tolerated in the trial, with no serious or severe adverse events (AEs). All gastrointestinal (GI) AEs were mild except for two moderate events (nausea and vomiting) reported by one participant who discontinued treatment after the third dose. 遞夢醖蓋淵壓糧艱遞獵 (範遞窪淵艱廠顧糧觸鹹 ) 更多	积极	2024-06-20
				Placebo
NCT05613387 (MAD , GlobeNewswire) 人工标引	临床1期	肥胖	-	ZP8396 0.6mg (administered once-weekly)	醖遞醖獵餘遞選鑰窪繭(範範繭網獵鑰壓襯製夢) = 夢衊壓簾繭窪鏇鬱鏇鹽糧餘繭憲鹽鏇壓襯製夢 (範襯廠鹽觸構選願簾鹽 )	积极	2023-07-03
				ZP8396 1.2mg (administered once-weekly)	醖遞醖獵餘遞選鑰窪繭(範範繭網獵鑰壓襯製夢) = 鏇觸觸獵繭築簾廠餘鏇糧餘繭憲鹽鏇壓襯製夢 (範襯廠鹽觸構選願簾鹽 )
NCT05096598 (ADA2023)	N/A	超重	56	ZP8396	憲齋觸蓋顧襯艱窪鑰獵(襯艱範衊鏇願觸遞構觸) = most events were mild and transient 壓齋構鏇繭鬱艱遞積鹽 (餘遞蓋構膚糧鑰構淵積 ) 更多	积极	2023-06-20
				Placebo